ACAD - ACADIA Pharmaceuticals Inc Stock Price, Fair Value and News

$25.86+0.43 (+1.69%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ACAD Price Action

Last 7 days

4.2%

Last 30 days

15.6%

Last 90 days

1.4%

Trailing 12 Months

58.7%

ACAD RSI Chart

ACAD Valuation

Market Cap

4.4B

Price/Earnings (Trailing)

16.75

Price/Sales (Trailing)

4.18

EV/EBITDA

Price/Free Cashflow

18.48

ACAD Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ACAD Fundamentals

ACAD Revenue

Revenue (TTM)

1.0B

Rev. Growth (Yr)

11.27%

Rev. Growth (Qtr)

5.32%

ACAD Earnings

Earnings (TTM)

261.2M

Earnings Growth (Yr)

119.07%

Earnings Growth (Qtr)

169.18%

ACAD Profitability

EBT Margin

26.14%

Return on Equity

28.47%

Return on Assets

19.63%

Free Cashflow Yield

5.41%

ACAD Investor Care

Shares Dilution (1Y)

1.68%

Diluted EPS (TTM)

1.55

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	996.3M	1.0B	1.0B	0
2024	813.8M	890.5M	929.2M	957.8M
2023	520.2M	550.9M	631.9M	726.4M
2022	493.1M	512.4M	511.5M	517.2M
2021	458.2M	463.4M	474.4M	484.1M
2020	366.2M	393.1M	419.1M	441.8M
2019	237.9M	264.0M	300.3M	339.1M
2018	158.5M	185.1M	207.8M	223.8M
2017	40.2M	63.0M	93.3M	124.9M
2016	4.4M	8.7M	13.0M	17.3M
2015	0	0	129.0K	118.0K
2014	758.0K	335.0K	110.0K	120.0K
2013	4.9M	4.7M	1.5M	1.1M
2012	2.1M	2.2M	5.1M	4.9M
2011	32.1M	22.1M	12.1M	2.1M
2010	0	18.3M	30.2M	42.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.

CEO	Mr. Stephen R. Davis J.D.
WEBSITE	https://acadia.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	540

ACADIA Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for ACADIA Pharmaceuticals Inc? What does ACAD stand for in stocks?

ACAD is the stock ticker symbol of ACADIA Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ACADIA Pharmaceuticals Inc (ACAD)?

As of Wed Dec 03 2025, market cap of ACADIA Pharmaceuticals Inc is 4.38 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACAD stock?

You can check ACAD's fair value in chart for subscribers.

Is ACADIA Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ACAD is over valued or under valued. Whether ACADIA Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact ACADIA Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACAD.

What is ACADIA Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, ACAD's PE ratio (Price to Earnings) is 16.75 and Price to Sales (PS) ratio is 4.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACAD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ACADIA Pharmaceuticals Inc's stock?

In the past 10 years, ACADIA Pharmaceuticals Inc has provided -0.033 (multiply by 100 for percentage) rate of return.